$16.75 Million in Sales Expected for Centogene N.V. (NASDAQ:CNTG) This Quarter

Share on StockTwits

Equities research analysts expect that Centogene N.V. (NASDAQ:CNTG) will announce sales of $16.75 million for the current quarter, Zacks Investment Research reports. Two analysts have made estimates for Centogene’s earnings. The lowest sales estimate is $16.62 million and the highest is $16.87 million. The company is scheduled to issue its next earnings report on Thursday, March 26th.

On average, analysts expect that Centogene will report full-year sales of $54.32 million for the current year, with estimates ranging from $53.96 million to $54.68 million. For the next financial year, analysts expect that the firm will report sales of $70.42 million, with estimates ranging from $69.18 million to $71.65 million. Zacks’ sales calculations are an average based on a survey of sell-side research firms that that provide coverage for Centogene.

A number of research analysts have recently weighed in on CNTG shares. Evercore ISI started coverage on Centogene in a research report on Monday, December 2nd. They issued an “outperform” rating and a $17.00 price target for the company. SVB Leerink restated an “outperform” rating on shares of Centogene in a research report on Monday, December 2nd. Zacks Investment Research cut Centogene from a “hold” rating to a “sell” rating in a research report on Monday, February 3rd. BTIG Research started coverage on Centogene in a research report on Monday, December 2nd. They issued a “buy” rating and a $18.00 price target for the company. Finally, Robert W. Baird began coverage on Centogene in a research report on Tuesday, December 3rd. They issued an “outperform” rating and a $15.00 price target for the company. One research analyst has rated the stock with a sell rating and four have given a buy rating to the stock. Centogene has an average rating of “Buy” and an average price target of $16.67.

Shares of CNTG stock opened at $17.00 on Friday. Centogene has a fifty-two week low of $7.80 and a fifty-two week high of $28.71. The firm has a fifty day moving average price of $14.37. The company has a debt-to-equity ratio of 1.44, a current ratio of 0.82 and a quick ratio of 0.77.

Several institutional investors and hedge funds have recently bought and sold shares of CNTG. Goldman Sachs Group Inc. acquired a new stake in shares of Centogene during the fourth quarter valued at $5,986,000. Victory Capital Management Inc. acquired a new stake in shares of Centogene during the fourth quarter valued at $2,952,000. Laurion Capital Management LP acquired a new stake in shares of Centogene during the fourth quarter valued at $226,000. New York State Common Retirement Fund acquired a new stake in shares of Centogene during the fourth quarter valued at $97,000. Finally, UBS Group AG acquired a new stake in shares of Centogene during the fourth quarter valued at $38,000. 8.28% of the stock is currently owned by institutional investors and hedge funds.

Centogene Company Profile

Centogene B.V. operates as a commercial-stage rare disease company worldwide. It focuses on transforming clinical and genetic data into medical solutions for patients, physicians, and pharmaceutical companies. The company develops rare disease platform, a data repository, which includes epidemiologic, phenotypic, and heterogenetic data that enhances methods for identifying and monitoring rare hereditary diseases and provide solutions that accelerate the development of orphan drugs.

Featured Article: What is the FTSE 100 index?

Get a free copy of the Zacks research report on Centogene (CNTG)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Centogene Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Centogene and related companies with MarketBeat.com's FREE daily email newsletter.



Latest News

Nuveen Asset Management LLC Has $48.56 Million Stake in Discovery Communications Inc.
Nuveen Asset Management LLC Has $48.56 Million Stake in Discovery Communications Inc.
Norges Bank Makes New Investment in Charles River Laboratories Intl. Inc
Norges Bank Makes New Investment in Charles River Laboratories Intl. Inc
Macquarie Group Ltd. Has $9.21 Million Stock Position in HCA Healthcare Inc
Macquarie Group Ltd. Has $9.21 Million Stock Position in HCA Healthcare Inc
Cardiovascular Systems  Given New $54.00 Price Target at Lake Street Capital
Cardiovascular Systems Given New $54.00 Price Target at Lake Street Capital
Janus Henderson Group PLC Buys New Stake in Associated Banc Corp
Janus Henderson Group PLC Buys New Stake in Associated Banc Corp
Brunswick Co.  Shares Purchased by Nuveen Asset Management LLC
Brunswick Co. Shares Purchased by Nuveen Asset Management LLC


© 2006-2020 Ticker Report